References
- HoyDBrooksPBlythFBuchbinderRThe epidemiology of low back painBest Pract Res Clin Rheumatol201024676978121665125
- Institute of Medicine (US) Committee on Advancing Pain Research, Care, and EducationRelieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and ResearchWashington (DC)National Academies Press2011
- WebsterLRMarkmanJMedical management of chronic low back pain: efficacy and outcomesNeuromodulation201417Suppl 2182325395113
- DagenaisSCaroJHaldemanSA systematic review of low back pain cost of illness studies in the United States and internationallySpine J20088182018164449
- NakamuraMNishiwakiYUshidaTToyamaYPrevalence and characteristics of chronic musculoskeletal pain in JapanJ Orthop Sci201116442443221678085
- Global Burden of Disease Study 2013 CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013Lancet2015386999574380026063472
- SmithHSSmithEJSmithBRDuloxetine in the management of chronic musculoskeletal painTher Clin Risk Manag2012826727722767991
- KonnoSOdaNOchiaiTAlevLA randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in Japanese patients with chronic low back painSpine (Phila Pa 1976)201641221709171727831985
- SkljarevskiVDesaiahDLiu-SeifertHEfficacy and safety of duloxetine in patients with chronic low back painSpine (Phila Pa 1976)20103513E578E58520461028
- SkljarevskiVOssannaMLiu-SeifertHA double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back painEur J Neurol20091691041104819469829
- SkljarevskiVZhangSDesaiahDDuloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trialJ Pain201011121282129020472510
- DworkinRHTurkDCMcDermottMPInterpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendationsPain2009146323824419836888
- MooreRACaiNSkljarevskiVTölleTRDuloxetine use in chronic painful conditions--individual patient data responder analysisEur J Pain2014181677523733529
- DworkinRHTurkDCWyrwichKWInterpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendationsJ Pain20089210512118055266
- UkiJMendozaTCleelandCSNakamuraYTakedaFA brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-JJ Pain Symptom Manage19981663643739879161
- WangFRubergSJGaynorPJHeinlothANArnoldLMEarly improvement in pain predicts pain response at endpoint in patients with fibromyalgiaJ Pain201112101088109421763211
- WilliamsonODSchroerMRuffDDOnset of response with duloxetine treatment in patients with osteoarthritis knee pain and chronic low back pain: a post hoc analysis of placebo-controlled trialsClin Ther201436454455124650448
- HäuserWSarzi-PuttiniPTölleTRWolfeFPlacebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysisClin Exp Rheumatol2012306 Suppl 74788723137770
- HäuserWBartram-WunnEBartramCReineckeHTölleTSystematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictorsPain201115281709171721429668
- TuttleAHTohyamaSRamsayTIncreasing placebo responses over time in U.S. clinical trials of neuropathic painPain2015156122616262626307858
- TurkDCDworkinRHRevickiDIdentifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with painPain2008137227628517937976
- JohnstonKDLuZRuddJALooking beyond 5-HT(3) receptors: a review of the wider role of serotonin in the pharmacology of nausea and vomitingEur J Pharmacol2014722132524189639
- SheltonRCSerotonin norepinephrine reuptake inhibitors: similarities and differencesPrim Psychiatry20091652535
- StahlSMMechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effectsJ Affect Disord199851321523510333979
- DeMartinisNAWinokurAEffects of psychiatric medications on sleep and sleep disordersCNS Neurol Disord Drug Targets200761172917305551
- StahlSMGradyMMMoretCBrileyMSNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressantsCNS Spectr200510973274716142213